The clinical potential of microRNAs
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
MicroRNAs are small noncoding RNAs that function to control gene expression. These small RNAs have been shown to contribute to the control of cell growth, differentiation and apoptosis, important features related to cancer development and progression. In fact, recent studies have shown the utility of microRNAs as cancer-related biomarkers. This is due to the finding that microRNAs display altered expression profiles in cancers versus normal tissue. In addition, microRNAs have been associated with cancer progression. In this review, the mechanisms to alter microRNA expression and their relation to cancer will be addressed. Moreover, the potential application of microRNAs in clinical settings will also be highlighted. Finally, the challenges regarding the translation of research involving microRNAs to the clinical realm will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111 · cited 1×
“The abnormal expression of several microRNAs have been observed in Burkitt’s lymphomas, B cell chronic lymphocytic leukemia (CLL) and in many solid cancer types, including breast, liver, lung, ovarian, cervical, colorectal and prostate [10-21].”
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053 · cited 2×
“The abnormal expression of several microRNAs have been observed in Burkitt’s lymphomas, B cell chronic lymphocytic leukemia (CLL) and in many solid cancer types, including breast, liver, lung, ovarian, cervical, colorectal and prostate [10-21].”
BackgroundSilencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“Inhibition of mature microRNA 2’OME-AMOs RNA-Liposome Complex Silence OncomiR [ 94 ]”
BackgroundUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 4×
“Lung Cancer miR-21, miR17-92 cluster, miR-106b/93/25 cluster; Let-7a, miR-143, miR-145 OncomiR; Tumor Suppressor [13,40,80,81]”
BackgroundInfluentialMicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010 · cited 1×
“Alternatively, changes in microRNA expression may be a downstream effect of potent oncogenes or tumor suppressors in the carcinogenesis process such as the modulation of miR34 by p53 [28].”
BackgroundSi, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600 · cited 1×
“Studies have shown that targeting of miR21, a microRNA that is overexpressed in many cancer types, by such methods effectively reduced tumor size in a xenograft mouse model based on MCF-7 cells [56].”
BackgroundLNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 1×
“Inhibition of mature microRNA LNA-antagomiR Unconjugated Silence OncomiR [ 99 ]”
BackgroundGene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., Liu, C.-G., Bhatt, D., Taccioli, C., & Croce, C. M. (2007) · JAMA · doi:10.1001/jama.297.17.1901 · Cited by 1,141
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · cited 2×
“Breast Cancer miR-21, miR-125b; miR126, miR-206, miR-335 OncomiR; Metastasis Suppressor [49,75,76]”
Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues
Liu, C.-G., Calin, G. A., Meloon, B., Gamliel, N., Sevignani, C., Ferracin, M., Dumitru, C. D., Shimizu, M., Zupo, S., Dono, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403293101 · Cited by 948 · cited 1×
“Microarray technology offers a powerful high-throughput tool to monitor the expression of thousands of microRNAs at once [2].”
BackgroundExtensive post-transcriptional regulation of microRNAs and its implications for cancer
Thomson, J. M., Newman, M., Parker, J. S., Morin-Kensicki, E. M., Wright, T., & Hammond, S. M. (2006) · Genes & Development · doi:10.1101/gad.1444406 · Cited by 877 · cited 1×
“Other possible mechanisms of altered microRNA expression include defective microRNA processing or post-transcriptional regulation, germ-line or somatic mutation and epigenetic changes such as methylation [6-9].”
BackgroundReal-time PCR quantification of precursor and mature microRNA
Schmittgen, T. D., Lee, E. J., Jiang, J., Sarkar, A., Yang, L., Elton, T. S., & Chen, C. (2008) · Methods · doi:10.1016/j.ymeth.2007.09.006 · Cited by 616 · cited 1×
“Quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) is another reliable and highly sensitive technique for microRNA detection, which is simple and robust, and only requires very small amounts of input total RNA [ 3 ].”
BackgroundCorsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406
Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice
Cerritelli, S. M., Frolova, E. G., Feng, C., Grinberg, A., Love, P. E., & Crouch, R. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00088-1 · Cited by 358
Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J.-L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010345 · Cited by 324 · cited 1×
“In addition, microRNAs play roles in regulating the expression of hypoxia-related genes, vascular endothelial growth factors [34-36].”
Background
Cited by
Personalized Medicine: Progress and Promise
Chan, I. S., & Ginsburg, G. S. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101446 · Cited by 399
Recent trends in cancer therapy: A review on the current state of gene delivery
Yahya, E. B., & Alqadhi, A. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119087 · Cited by 235
The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer
Labbaye, C., & Testa, U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-13 · Cited by 228
An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model
Selvamani, A., Sathyan, P., Miranda, R. C., & Sohrabji, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032662 · Cited by 217
“In conclusion, a rapidly growing body of literature on miRNA’s role in cancer [66], neurodegenerative diseases [67–72] and MicroRNA Therapy for Stroke”
BackgroundTargeting MicroRNAs in Cancer Gene Therapy
Ji, W., Sun, B., & Su, C. (2017) · Genes · doi:10.3390/genes8010021 · Cited by 174
“They have an ability to inhibit or promote the expression of many related genes, which can affect several cell-signaling pathways essential to tumor development and progression, such as cell proliferation, differentiation, mobility and apoptosis [8,9].”
Background
Metadata
- Authors
- Budhu, A., Ji, J., & Wang, X. W.
- Venue
- Journal of Hematology & Oncology
- Published
- 2010-10-06
- Volume
- 3
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2162324431
- Cited by
- 109
- References
- 20
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.